Drug search by name

Geodon and QT interval prolongation

Result of checking the interaction of drug Geodon and disease QT interval prolongation for safety when used together.

Check result:

Geodon <> QT interval prolongation

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of ziprasidone is contraindicated in patients with congenital or acquired QT interval prolongation syndromes, recent acute myocardial infarction, uncompensated heart failure, or a history of cardiac arrhythmias. Ziprasidone can prolong the QT interval of the electrocardiogram in a dose-related manner. The risk of torsade de pointes is progressively increased as the degree of prolongation becomes greater. In clinical trials, ziprasidone increased the QTc interval by approximately 10 msec at the highest recommended daily dosage of 160 mg compared to placebo. The manufacturer states that ziprasidone should be discontinued in patients with persistent QTc measurements greater than 500 msec.

Electrolyte disturbances such as hypokalemia and hypomagnesemia may augment the prolongation effect of ziprasidone on the QT interval and should be corrected prior to institution of ziprasidone therapy. In addition, patients who experience frequent, severe, or prolonged diarrhea may be subject to electrolyte losses and should be followed closely and managed accordingly during therapy with ziprasidone.

References:

Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82
"Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.

Geodon

Generic Name: ziprasidone

Brand Name: Geodon

Synonyms: n.a.

What is Geodon?